A GLOBAL PHASE 2 TRIAL OF NANATINOSTAT AND VALGANCICLOVIR IN PATIENTS WITH RELAPSED/REFRACTORY EBV-POSITIVE PERIPHERAL T-CELL LYMPHOMAS (NAVAL-1 STAGE 1-2)
M Lacerdaa,b, R Nairc, H Changd, N Goldschmidte, B Haverkosf, H Huag, L Zinzanih, D Stricklandi, E Gonzálezj
a Universidade da Região de Joinville (UNIVILLE), Joinville, Brazil
b Centro de Hematologia e Oncologia, Joinville, Brazil
c Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, United States
d Division of Hematology, Chang Gung University, Taoyuan, Taiwan
e Department of Hematology, Hadassah Medical Center, Jerusalem, Israel
f Division of Hematology, University of Colorado, Denver, United States
g Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
h Department of Medicine and Surgical Services, University of Bologna, Bologna, Italy
i Viracta, Inc., Cardiff, United States
j Department of Hematology, Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain
Ver másRead
448
Timeswas read the article
131
Total PDF
317
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 7 | 11 | 2 | 13 |
| 2025 6 | 36 | 25 | 61 |
| 2025 5 | 46 | 5 | 51 |
| 2025 4 | 40 | 7 | 47 |
| 2025 3 | 47 | 11 | 58 |
| 2025 2 | 34 | 16 | 50 |
| 2025 1 | 29 | 9 | 38 |
| 2024 12 | 19 | 8 | 27 |
| 2024 11 | 33 | 30 | 63 |
| 2024 10 | 22 | 18 | 40 |
